Skip to content

Quadratus Lumborum Block for Total Hip Arthroplasty

Quadratus Lumborum (QL) Nerve Block for Patients Undergoing Primary Total Hip Arthroplasty (THA)

Status
Enrolling by invitation
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05247255
Enrollment
80
Registered
2022-02-18
Start date
2022-03-29
Completion date
2027-01-01
Last updated
2026-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Keywords

quadratus lumborum nerve block, analgesia, total hip arthroplasty, postoperative outcomes

Brief summary

The quadratus lumborum (QL) block is a fascial plane block that has been described to provide analgesia from T7-L3 dermatomes. The investigators aim to evaluate the efficacy of QL blocks in patients undergoing primary total hip arthroplasty (THA).

Detailed description

Investigators will enroll subjects planned for primary THA and allocate them into receiving a QL block with either saline or ropivacaine. Primary outcome will be pain scores over the first 48 hours after surgery.

Interventions

DRUGActive Comparator

QL block with 0.25% ropivacaine

DRUGPlacebo Comparator

QL block with saline

Sponsors

University of California, Los Angeles
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult subjects undergoing elective primary total hip arthroplasty

Exclusion criteria

* patients age \< 18, * documented allergy to local anesthetic * presence of peripheral neuropathy * patients with current long term opioid use defined as receiving an opioid on most days in a 90 day period * patients with a contraindication to spinal and regional anesthesia such as coagulopathy or infection at the site of the regional technique.

Design outcomes

Primary

MeasureTime frameDescription
Pain scoreUp to 48 hrs post opPain scores will be assessed over 48hrs postop using the visual analog score

Secondary

MeasureTime frameDescription
Opioid usageUp to 48 hrs post opTotal morphine-equivalent will be calculated at 0-24hrs and 24-48hrs postop.
Time to first standUp to 1 week post surgeryThe period between the end of surgery and the patient's first successful attempt at standing, with or without the assistance of devices (i.e. walker, cane) or staff assistance.
Time to first ambulationUp to 1 week post surgeryTime to first ambulation of 50 feet or more, with or without the help of assist devices (i.e. walker, cane) or staff assistance.
Ambulation distanceUp to 1 week post surgeryThis data point will be measured in feet and will be determined by the distance ambulated during the patient's first ambulation attempt after surgery, regardless of the length of ambulation (This distance will be counted regardless of whether the patient reaches the 50 feet requirement to be counted as the "time to first ambulation).
Length of hospital stayUntil discharge from hospital, up to 1 week post surgeryNumber of days in the hospital from postoperative day 0 to discharge
Patient satisfactionUntil day of discharge from the hospital, up to 1 week post surgeryPatient satisfaction score will be assessed on day of discharge as measured by a 5-point scale with 1 = terrible, 2 = poor, 3 = satisfactory, 4 = good, and 5 = excellent.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORPamela Chia, MD

University of California, Los Angeles

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 6, 2026